Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. - sprookjes - yvandenbroek - TriplyDB

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

http://www.wikidata.org/entity/Q37350801

about

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives Marine Invertebrate Metabolites with Anticancer Activities: Solutions to the "Supply Problem"The value of trabectedin in the treatment of soft tissue sarcoma Marine Drugs Regulating Apoptosis Induced by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)Advances in sarcoma diagnostics and treatment Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas UK guidelines for the management of soft tissue sarcomas Major clinical research advances in gynecologic cancer in 2015 Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas The importance of treating by histological subtype in advanced soft tissue sarcoma.Advances and controversies in the management of soft tissue sarcomas.Treatment of soft tissue sarcoma: a focus on earlier stages.Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline.Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma.In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug To Treat Soft Tissue Sarcoma SEOM Clinical Guideline of management of soft-tissue sarcoma (2016).Current Concepts in Non-Gastrointestinal Stromal Tumor Soft Tissue Sarcomas: A Primer for Radiologists.Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas Phase III Soft Tissue Sarcoma Trials: Success or Failure?Targeted therapy for soft tissue sarcomas in adolescents and young adults.Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.Olaratumab for advanced soft tissue sarcoma.Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials.Olaratumab for the treatment of soft-tissue sarcoma.Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.Review of past and present clinical cases with a view to future treatment options.Intensity of recent years in the investigation of soft tissue sarcoma.

P2860

Q26738346-92E93CAC-BA07-41D5-8599-5CA91FADF04D Q26741817-B5F9881A-F7F9-431E-9EB9-5F86E676611D Q26745502-292905D9-B83C-4096-9BD9-06740126C9DF Q26746924-D6586A75-11BA-47D9-8500-AB7EDCB04F08 Q26772855-D5FC5D9E-8934-4833-B0F2-1EF232C22EB6 Q26859211-4B889810-9506-4636-8BC8-370B2A1639EF Q28069695-CAA50003-897D-4BE3-979F-83E78F93C8BD Q28074125-4F4638CC-BFFD-4FA2-9A03-C573212B54AB Q28076210-3A9D923D-D24A-4DAD-80E4-3F8D6375C28B Q28076730-F7CB3A94-AFBE-4908-8BE8-752F721B4887 Q28077183-3D97BFDF-7361-4843-8422-9003E6DBD787 Q28078116-AAEC5A31-E6F2-4068-B5DF-117372A7D295 Q30240223-6FD4F9F9-A029-41CF-A553-2A62B59882D6 Q30240228-E4556386-62E4-4C3F-8D1C-BB193ECE9EFC Q30240235-B4436E55-BBF4-4044-BEBB-CB688651B67A Q33434141-F2826F73-FF61-4EBD-9A26-CB66C006DB33 Q33439682-AF5D0B6B-D938-4B33-93A5-8F4EF7A75408 Q33442984-F572FF3A-B62F-4B4F-87C7-A3BD86E61E71 Q33617922-E0FF40E7-1F9E-44DB-8433-8CEC5E276AAB Q33657779-DF24D1A7-C2B6-4C35-8586-F0BE5571C39B Q33890846-02A8AC98-5D64-4DA9-8685-A7900F09D08A Q36304907-7DD3CD80-B608-46EB-B4BF-331101FA0745 Q36530034-927CC6EF-712D-421E-8F74-0CDFAD6D713A Q36995072-B472D01D-6C2F-4648-97FB-E8BF8BCF03AB Q37137443-C946AE10-97F2-4E5C-BA45-0663BDC7FB2D Q37475143-EE403E34-1DD3-4C4E-8BE3-7FD6CB5F412A Q37589535-9A8FB901-37E7-4696-A392-8BE60006882C Q37644536-4A623B81-5F17-40E0-A9EC-1371CCC08B97 Q37669484-2FD30325-3256-45BB-B471-FA9883FA5A0B Q37716872-C340F37D-8F92-4A69-A13D-D22A32ED0B35 Q37742014-A333B39A-D943-4D30-BC6A-9CE32E66A99C Q37747771-809B12CC-9D4E-47E8-90D4-02857EFF4A89 Q38374836-D547A182-6ABC-4CC1-8A65-F4E84FBAD994 Q38377472-C1FC0B28-5B08-4EE2-8449-E82DE6F00A50 Q38611179-DA7E0918-CB59-41A7-BC7C-F46D8C039284 Q38651664-87437A98-B5B6-43E6-BACC-2F5A85A853F6 Q38654374-BAB3DEE6-6305-47DD-B44C-F039630B919B Q38688042-4AF4D8BA-B152-4A84-8BF3-81092758BCED Q38688923-0A614340-AE86-4533-A139-985E025856FE Q38688925-46DFBB99-4D6D-4788-B96A-23733E5FD22D

P2860

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

http://www.wikidata.org/entity/Q37350801

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 September 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy and Safety of Trabect ...... ed Multicenter Clinical Trial.

@en

Efficacy and Safety of Trabect ...... ed Multicenter Clinical Trial.

@nl

type

label

Efficacy and Safety of Trabect ...... ed Multicenter Clinical Trial.

@en

Efficacy and Safety of Trabect ...... ed Multicenter Clinical Trial.

@nl

prefLabel

Efficacy and Safety of Trabect ...... ed Multicenter Clinical Trial.

@en

Efficacy and Safety of Trabect ...... ed Multicenter Clinical Trial.

@nl

P1433

Q37350801-CFCB7246-1551-470E-B389-EC639EE83628

P1476

Q37350801-1A3BBE04-A1DE-4CCA-845D-10899B51A180

P2093

Q37350801-03626E4E-7F98-4AD0-851D-227A11323304

Q37350801-0DA9CDD1-144A-4F4D-A658-C10B576ACDCF

Q37350801-157A12BA-0874-4B65-8D3C-B8EA7D61F0DD

Q37350801-34717C47-2510-4222-AB22-5CF2D8878FA5

Q37350801-3FED59C9-BBB1-44E3-9CA3-D2C28588A5A7

Q37350801-4B553FD3-97F9-4F49-AEA4-DDDA82B4FA1B

Q37350801-A12CDCAD-F1B9-47FC-A235-9A0C8F627E44

Q37350801-A71FC962-8953-4E62-BB1B-6DDF7B98B17F

Q37350801-BDA50CBE-67B4-4BCA-AA87-37AEC4AA7218

Q37350801-C7E8C19E-3684-4DF0-892E-CFC3DE5C9F1A

P2860

Q37350801-02047A05-D279-4583-8DCC-67D92C7EBF93

Q37350801-07CB9567-B82D-4194-BC94-014717572EC1

Q37350801-0A2FA3FB-D7AC-4640-95AC-0E07222BEE68

Q37350801-0D0C71B1-9930-4448-99C4-C0412B6F6C53

Q37350801-0E96B961-C3DD-4F22-9AC3-A706296447B1

Q37350801-23A00EB8-8F7E-4529-80AD-81ACFEFD1EF8

Q37350801-28121987-ABFB-42A7-A360-0BF24A328747

Q37350801-40E4D419-C176-4636-A603-F2D2FE6A077F

Q37350801-46F3F942-1BC7-4E0D-83AE-C6DC161E5F89

Q37350801-4778B82C-B886-49C5-B61D-E4A2896C49D1

P304

Q37350801-5B850A40-E544-4AD6-8329-FE8C59810B55

P31

Q37350801-4A131543-DDB3-433C-BA12-16481753B514

P356

Q37350801-F8E5ED2C-1E7D-4A43-9062-1D876A967E88

P407

Q37350801-9D30DCB6-64E5-458E-BD3F-06B41C035C33

P433

Q37350801-2410B7B5-0943-49B2-91A2-F85E271C96A6

P478

Q37350801-19034E26-28B4-432F-B5DB-CC09BCAE4B85

P50

Q37350801-624FA16D-D1C8-45CA-9F09-ACAA8C7ADAC0

Q37350801-E4A5A8B5-3BC3-4CD9-80B1-724418DE39CA

Q37350801-E93BF2B0-9E29-4C61-B942-66E1EBA56AA4

P577

Q37350801-1877913C-CDC9-47BC-8B42-C651DA4A1A97

P698

Q37350801-0A3DB2A9-06B6-47F8-B390-B52CD59EC8EF

P921

Q37350801-1153AA25-897E-4941-9FB1-4A1F9614EA4D

Q37350801-5456302F-C680-4F1C-BF8E-1109EC765C57

Q37350801-A5A96C5F-8B10-4A1A-A7C1-43BB3584E175

P932

Q37350801-3DDD7719-3FBE-4276-B6A6-EBD9A28101F4

P356

JCO.2015.62.4734

P1433

Journal of Clinical Oncology

P1476

Efficacy and Safety of Trabect ...... zed Multicenter Clinical Trial

@en

P2093

Alexander Spira

http://www.w3.org/2001/XMLSchema#string

Andrew Dean

http://www.w3.org/2001/XMLSchema#string

Anthony Elias

http://www.w3.org/2001/XMLSchema#string

Arthur Staddon

http://www.w3.org/2001/XMLSchema#string

Brian A Van Tine

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

Hussein Tawbi

http://www.w3.org/2001/XMLSchema#string

Kristen Ganjoo

http://www.w3.org/2001/XMLSchema#string

Margaret von Mehren

http://www.w3.org/2001/XMLSchema#string

Martee L Hensley

http://www.w3.org/2001/XMLSchema#string

P2860

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

Preclinical and clinical results with the natural marine product ET-743.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

P304

786-793

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.62.4734

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26371143

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

multicenter trial

P932

5070559

http://www.w3.org/2001/XMLSchema#string